The present study evaluates the downregulation of biomarkers in the RAS/MAPK and PI3K/AKT pathways by IHC before and after lapatinib administration in order to determine the mechanism of action of this drug in DCIS. Here, AKT1 is linked to ductal breast carcinoma in situ.